Cyclodextrin-catalyzed deacetylation of spironolactone is pH and cyclodextrin dependent

Journal of Pharmaceutical Sciences

Volumn 89, Issue 2, 2000, Pages 241-249

  Jarho, Pekka ^a,b   Velde, David Vander ^a   Stella, Valentino J ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Cyclodextrins; Solubility; Spironolactone; Stability

Indexed keywords

ALDOSTERONE ANTAGONIST; CYCLODEXTRIN; SPIRONOLACTONE;

ARTICLE; CATALYSIS; DEACETYLATION; DRUG DEGRADATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PH;

EID: 0034004009     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6017(200002)89:2<241::AID-JPS11>3.0.CO;2-0     Document Type: Article

References (25)

1. Rajewski RA, Stella VJ. 1996. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J Pharm Sci 85:1142-1169.
2. Loftsson T, Brewster ME. 1996. Pharmaceutical applications of cyclodextrins 1. Drug solubilization and stabilization. J Pharm Sci 85:1017-1025.
3. 1. Chem Pharm Bull 27:435-441.
4. Loftsson T, Olafsdottir BJ. 1991. Cyclodextrin-accelerated degradation of β-lactam antibiotics in aqueous solutions. Int J Pharm 67:R5-R7.
5. Loftsson T, Johannesson HR. 1994. The influence of cyclodextrins on the stability of cephalothin and aztreonam in aqueous solutions. Pharmazie 49: 292-293.
6. Fromming K-H, Szejtli J. 1994. Cyclodextrins in pharmacy. Dordrecht: Kluwer.
7. Pitha J, Milecki J, Fales H, Pannel L, Uekama K. 1986. Hydroxypropyl-β-cyclodextrin: preparation and characterization: effect on solubility of drugs. Int J Pharm 29:73-82.
8. Yusuff N, York P. 1991. Spironolactone-cyclodextrin complexes: phase solubility and ultrafiltration studies. Int J Pharm 73:9-15.
9. El Shaboury MH. 1990. Physical properties and dissolution profiles of tablets directly compressed with β-cyclodextrin. Int J Pharm 63:95-100.
10. Seo H, Tsuruoka M, Hashimoto T, Fujinaga T, Otagiri M, Uekama K. 1983. Enhancement of oral bioavailability of spironolactone by β-and γ-cyclodextrin complexations. Chem Pharm Bull 31:286-291.
11. Yusuff NT, York P, Chrystyn H, Bramley PN, Swallow RD, Tuladhar BR, Losowsky MS. 1991. Improved bioavailability from a spironolactone beta-cyclodextrin complex. Eur J Clin Pharmacol 40:507-511.
12. Abosehmah-Albidy AZM, York P, Wong V, Losowsky MS, Chrystyn H. 1997. Improved bioavailability and clinical response in patients with chronic liver disease following the administration of spironolactone: β-cyclodextrin complex. Br J Clin Pharmacol 44:35-39.
13. Soliman OAE, Kimura K, Hirayama F, Uekama K, El-Sabbagh HM, Helmy AE, Hashim FM. 1997. Amorphous spironolactone-hydroxypropylated cyclodextrin complex with superior dissolution and oral bioavailability. Int J Pharm 149:73-83.
14. Andersen FM, Bundgaard H. 1983. Inclusion complexation of spironolactone with cyclodextrins. Arch Pharm Chem Sci Ed 11:7-14.
15. Szejtli J. 1988. Cyclodextrin technology. Dordrecht: Kluwer. p 244-245.
16. Wouessidjewe D, Crassous A, Duchene D, Coleman A, Rysanec N, Tsoucaris G, Perly B, Djedaini, F. 1989. Inclusion of spironolactone in cyclomaltoheptaose: a guest affected by the hospitality of the host. Carbohydr Res 192:313-322.
17. Kaukonen AM, Kilpelainen I, Mannermaa J-P. 1997. Water-soluble β-cyclodextrins in paediatric oral solutions of spironolactone: solubilization and stability of spironolactone in solutions of β-cyclodextrin derivatives. Int J Pharm 159:159-170.
18. Higuchi T, Connors KA. 1965. Phase-solubility techniques. Adv Anal Chem Instr 4:117-212.
19. Sutter JL, Lau EPK. Spironolactone. In: Florey K, editor. 1975. Analytical profiles of drug substances. Vol. 4. New York: Academic, p 431-451.
20. Okimoto K, Rajewski RA, Uekama K, Jona JA, Stella VJ. 1996. The interaction of charged and uncharged drugs with neutral (HP-β-CD) and anionically charged (SBE7-β-CD) β-cyclodextrins. Pharm Res 13:256-264.
21. Zia V, Rajewski RA, Bornancini ER, Luna EA, Stella VJ. 1997. Effect of alkyl chain length and degree of substitution on the complexation of sulfoalkyl ether β-cyclodextrin with steroids. J Pharm Sci 86:220-224.
22. Pramar Y, Gupta VD. 1991. Preformulation studies of spironolactone: effect of pH, two buffer species, ionic strength, and temperature on stability. J Pharm Sci 80:551-553.
23. 2 in solution. Int J Pharm 106:135-140.
24. Choudhury S, Mitra AK. 1993. Kinetics of aspirin hydrolysis and stabilization in the presence of 2-hydroxypropyl-β-cyclodextrin. Pharm Res 10: 156-159.
25. Solomons TWG. 1988. Organic chemistry. 4th ed. New York: Wiley.